Alpha Tau Medical Ltd. Ordinary Shares DRTS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T01:00:52.057Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:14:17.314925853Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T00:55:11.858043+00:00
Alpha Tau Medical Ltd. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 17.00 | 123.1% | 23.4% | 11.89 | 129.6% | 17.7% |
| 25Δ | 16.33 | 113.4% | 19.0% | 12.51 | 124.9% | 13.9% |
| 30Δ | 15.66 | 103.8% | 14.7% | 12.81 | 120.6% | 12.5% |
| 35Δ | 15.00 | 94.2% | 10.4% | 13.12 | 116.4% | 11.2% |
| 40Δ | 14.65 | 104.4% | 9.7% | 13.42 | 112.1% | 9.8% |
| 45Δ | 14.31 | 114.6% | 9.0% | 13.73 | 107.8% | 8.5% |
| 50Δ | 13.97 | 124.7% | 8.4% | 14.03 | 103.5% | 7.2% |
| 55Δ | 13.63 | 134.9% | 7.7% | 14.33 | 99.2% | 5.8% |
| 60Δ | 13.28 | 145.1% | 7.0% | 14.64 | 94.9% | 4.5% |
| 65Δ | 12.94 | 155.2% | 6.4% | 14.94 | 90.6% | 3.1% |
| 70Δ | 12.60 | 165.4% | 5.7% | 15.32 | 87.5% | 2.5% |
| 75Δ | 12.07 | 168.0% | 4.8% | 15.72 | 84.7% | 2.0% |
| 80Δ | 11.47 | 167.7% | 3.7% | 16.12 | 81.9% | 1.6% |
20Δ
- Pseudo strike
- 17.00
- IV
- 123.1%
- B/E move
- 23.4%
- Pseudo strike
- 11.89
- IV
- 129.6%
- B/E move
- 17.7%
25Δ
- Pseudo strike
- 16.33
- IV
- 113.4%
- B/E move
- 19.0%
- Pseudo strike
- 12.51
- IV
- 124.9%
- B/E move
- 13.9%
30Δ
- Pseudo strike
- 15.66
- IV
- 103.8%
- B/E move
- 14.7%
- Pseudo strike
- 12.81
- IV
- 120.6%
- B/E move
- 12.5%
35Δ
- Pseudo strike
- 15.00
- IV
- 94.2%
- B/E move
- 10.4%
- Pseudo strike
- 13.12
- IV
- 116.4%
- B/E move
- 11.2%
40Δ
- Pseudo strike
- 14.65
- IV
- 104.4%
- B/E move
- 9.7%
- Pseudo strike
- 13.42
- IV
- 112.1%
- B/E move
- 9.8%
45Δ
- Pseudo strike
- 14.31
- IV
- 114.6%
- B/E move
- 9.0%
- Pseudo strike
- 13.73
- IV
- 107.8%
- B/E move
- 8.5%
50Δ
- Pseudo strike
- 13.97
- IV
- 124.7%
- B/E move
- 8.4%
- Pseudo strike
- 14.03
- IV
- 103.5%
- B/E move
- 7.2%
55Δ
- Pseudo strike
- 13.63
- IV
- 134.9%
- B/E move
- 7.7%
- Pseudo strike
- 14.33
- IV
- 99.2%
- B/E move
- 5.8%
60Δ
- Pseudo strike
- 13.28
- IV
- 145.1%
- B/E move
- 7.0%
- Pseudo strike
- 14.64
- IV
- 94.9%
- B/E move
- 4.5%
65Δ
- Pseudo strike
- 12.94
- IV
- 155.2%
- B/E move
- 6.4%
- Pseudo strike
- 14.94
- IV
- 90.6%
- B/E move
- 3.1%
70Δ
- Pseudo strike
- 12.60
- IV
- 165.4%
- B/E move
- 5.7%
- Pseudo strike
- 15.32
- IV
- 87.5%
- B/E move
- 2.5%
75Δ
- Pseudo strike
- 12.07
- IV
- 168.0%
- B/E move
- 4.8%
- Pseudo strike
- 15.72
- IV
- 84.7%
- B/E move
- 2.0%
80Δ
- Pseudo strike
- 11.47
- IV
- 167.7%
- B/E move
- 3.7%
- Pseudo strike
- 16.12
- IV
- 81.9%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 63.00% | |
| 67.53% | |
| 65.11% | |
| 71.14% | |
| 70.66% | |
| 74.47% | |
| 80.52% | |
| 79.78% | |
| 82.32% | |
| 83.36% |
Biotechnology
DRUG
Description unavailable
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Description unavailable
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral…
More →